<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to determine the relationship between bone marrow (bm) endosteal cells (<z:chebi fb="107" ids="27789">EDC</z:chebi>) and hemopoietic progenitors, we have analyzed the immunophenotype of <z:chebi fb="107" ids="27789">EDC</z:chebi> using various antibodies (Ab) against mesenchymal antigens </plain></SENT>
<SENT sid="1" pm="."><plain>The Ab were applied on paraffin sections of <z:mpath ids='MPATH_458'>normal</z:mpath> bm (iliac crest, n=17; talus, n=1; phalanx, n=1), myeloregenerative bm (after chemotherapy), and <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> (<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), n=8; <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), n=6; <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), n=14; severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA), n=4; <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET), n=2; idiopathic (primary) osteomyelo-<z:mp ids='MP_0003045'>fibrosis</z:mp> (IMF), n=1; <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), n=1) </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> bm, <z:chebi fb="107" ids="27789">EDC</z:chebi> were found to react with Ab against vimentin, tenascin, alpha-smooth muscle actin, osteocalcin, CD51, and CD56, but did not react with Ab against CD3, CD15, CD20, CD34, CD45, CD68, or CD117 </plain></SENT>
<SENT sid="3" pm="."><plain>An identical phenotype of <z:chebi fb="107" ids="27789">EDC</z:chebi> was found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, SAA, ET, IMF, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, myeloregenerative bm, and peripheral bones lacking active hemopoiesis (talus, phalanx) </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:mp ids='MP_0005481'>CML</z:mp>, <z:chebi fb="107" ids="27789">EDC</z:chebi> reacted with Ab to CD51, but did not react with Ab to CD56 </plain></SENT>
<SENT sid="5" pm="."><plain>Based on their unique antigen profile, <z:chebi fb="107" ids="27789">EDC</z:chebi> were enriched from <z:mpath ids='MPATH_458'>normal</z:mpath> bm by enzyme digestion and cell sorting </plain></SENT>
<SENT sid="6" pm="."><plain>However, these enriched cells (CD56+, CD45-, CD34-) did not give rise to hemopoietic cells under the culture conditions used, i.e. in the presence of the growth factors IGF-1, bFGF, SCF, IL-3, and GM-CSF Together, our data do not support the hypothesis that <z:chebi fb="107" ids="27789">EDC</z:chebi> are totipotent mesenchymal progenitors giving rise to hemopoietic cells </plain></SENT>
</text></document>